title: Biomarkers of 3-nitropropionic acid (3-NPA)-induced mitochondrial dysfunction as indicators of neuroprotection.
abstract: In humans or animals, symptoms of mitochondrial energy dysfunction may be produced by mutations or inborn errors of the necessary enzymes, as well as by enzyme inhibitors or uncouplers of the oxidative phosphorylation process. 3-Nitropropionic acid (3-NPA) is a toxin that is sometimes produced on moldy crops (sugarcane, peanuts, etc.) in amounts sufficient to cause severe neuromuscular disorders when consumed by humans. In vitro, 3-NPA irreversibly inactivates SDH, a Complex II respiratory enzyme important for mitochondrial energy production. We have been studying biomarkers of 3-NPA exposure in the expectation that such markers may be useful in the screening process to identify neuroprotective agents against neurotoxicity produced by mitochondrial energy dysfunction. Animals were sacrificed at various times after 3-NPA exposure for histochemical visualization of SDH activity and measurement of immediate postmortem rectal temperature. 3-NPA-treated rats experienced progressive hypothermia that reached a loss of 3 degrees C or more in core body temperature by three hours after dosing. The optical density of the SDH stain in brain was reduced, following a similar time course, most prominently in the cerebellum and least sharply in the thalamus. Some rats were given injections of L-carnitine (an enhancer of fatty acid transport) either alone, or as a pretreatment prior to a dose of 3-NPA. Although L-carnitine deficiency by itself can produce mitochondrial dysfunction, pretreatment with L-carnitine was of limited efficacy at overcoming the effects of 3-NPA on either body temperature or quantitative SDH histochemistry. Body temperature and SDH histochemistry may be useful biomarkers for evaluating the efficacy of neuroprotective agents against lower doses of 3-NPA, against other pharmacological models of mitochondrial dysfunction, or even against genetic mitochondrial diseases.
authors.affiliation: Division of Neurotoxicology, National Center for Toxicological Research, USFDA, 3900 NCTR Drive, Jefferson, Arkansas 72079, USA. AScallet@NCTR.FDA.GOV
authors.forename: A C
authors.initials: AC
authors.lastname: Scallet
authors.forename: P L
authors.initials: PL
authors.lastname: Nony
authors.forename: R L
authors.initials: RL
authors.lastname: Rountree
authors.forename: Z K
authors.initials: ZK
authors.lastname: Binienda
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D001831:Body Temperature / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D003292:Convulsants / Q000494:pharmacology*; D008297:Male; D017240:Mitochondrial Myopathies / Q000201:enzymology; D009574:Nitro Compounds; D011422:Propionates / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013385:Succinate Dehydrogenase / Q000187:drug effects* / Q000378:metabolism
chemical_list: D015415:Biomarkers; D003292:Convulsants; D009574:Nitro Compounds; D011422:Propionates; D013385:Succinate Dehydrogenase; C015392:3-nitropropionic acid